TABLE 1

Characterization of the A. baumannii clinical isolate panel used in this studya

Strain designationStrain isolationMLSTMIC (μg/ml) of drug:
CountryYrGENTMEROCIPTZPCTXSXTSAMTET
ATCC 17978France19517720.518/416>8/1524/22
BV94USA20112>12832256>256/4>256>8/15216/832
BV95Colombia201025164128256/432>8/15216/8>256
BV172Israel20122>1286432256/4>256>8/15264/32>256
BV173Greece20122>128>64128>256/4>256>8/152128/64>256
BV174USA20122864256256/4256>8/15232/1632
BV175Turkey2012212832256>256/4256>8/15232/16256
BV185Mexico20132>128>64128>256/4>256>8/15264/32256
BV186USA201321664256>256/4>256>8/15232/168
BV187USA201323264256>256/4>256>8/15216/88
BV189Spain2013212832128>256/4256>8/15232/1616
BV190Greece20121>1286464>256/4>256>8/15264/32256
BV191China20132>128>64256>256/4>256>8/152128/64>256
ATCC 25922 (quality control)1<0.06<0.254/4<0.250.125/2.344/22
  • a Abbreviations: CIP, ciprofloxacin; CTX, cefotaxime; GENT, gentamicin; MERO, meropenem; MLST, multilocus sequence type; SAM, ampicillin-sulbactam; SXT, trimethoprim-sulfamethoxazole; TET, tetracycline; TZP, piperacillin-tazobactam. Classification of antibiotic resistance was done according to breakpoints published by the Clinical and Laboratory Standards Institute: susceptible (italics), intermediate (underlined), and resistant (bold) (34).